Treatment of Unresectable Hepatocellular Cancer With Opioid Growth Factor
Treatment of Unresectable Hepatocellular Cancer With Opioid Growth Factor: a Phase I Study
Sponsor: Penn State University
A PHASE1 clinical study on Hepatocellular Cancer, this trial is completed. The trial is conducted by Penn State University and has accumulated 7 data snapshots since 2008. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
-
Aug 2017 — Jun 2018 [monthly]
Completed PHASE1
Status: Unknown Status → Completed
▶ Show 2 earlier versions
-
Feb 2017 — Aug 2017 [monthly]
Unknown Status PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status PHASE1
First recorded
Jun 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Penn State University
- University of Missouri-Columbia
For direct contact, visit the study record on ClinicalTrials.gov .